首页 > 最新文献

BMC Clinical Pathology最新文献

英文 中文
Biphasic low-grade nasopharyngeal papillary adenocarcinoma: a case report and literature review. 双期低级别鼻咽乳头状腺癌1例报告并文献复习。
Q2 Medicine Pub Date : 2018-10-04 eCollection Date: 2018-01-01 DOI: 10.1186/s12907-018-0076-1
Hidenori Yokoi, Yuichi Terado, Masachika Fujiwara, Yuma Matsumoto, Tetsuya Ikeda, Koichiro Saito

Background: Low-grade nasopharyngeal papillary adenocarcinoma (LGNPPA) is distinctly rare. We report a patient with a uniquely biphasic LGNPPA; additionally, we review similar tumors reported in the literature.

Case presentation: A 56-year-old man presented with an asymptomatic pedunculated tumor in the vault of the nasopharynx, at the junction of the nasal septum and the roof, which was discovered during screening for laryngeal cancer. To obtain a definitive diagnosis, the patient underwent endoscopic endonasal surgery under general anesthesia. Immunohistochemical analysis of the tumor revealed it to be an LGNPPA with a prominent spindle cell component.

Conclusion: To our knowledge, this is the fourth reported LGNPPA exhibiting a spindle cell component and the second with a prominent pathological condition. The prognosis of LGNPPA is usually excellent. Therefore, it is important for clinicians to scrutinize the lesion's pathology to avoid unnecessary, disfiguring surgery.

背景:低级别鼻咽乳头状腺癌(LGNPPA)非常罕见。我们报告一个独特的双期LGNPPA患者;此外,我们回顾了文献中报道的类似肿瘤。病例介绍:一名56岁男性,在鼻中隔和鼻顶交界处的鼻咽部穹隆处发现无症状带蒂肿瘤,在喉癌筛查时发现。为了获得明确的诊断,患者在全身麻醉下进行了鼻内窥镜手术。肿瘤的免疫组化分析显示它是一种具有突出梭形细胞成分的LGNPPA。结论:据我们所知,这是第四个报道的具有纺锤体细胞成分的LGNPPA,第二个具有突出的病理状况。LGNPPA的预后通常很好。因此,重要的是临床医生仔细检查病变的病理,以避免不必要的,毁容手术。
{"title":"Biphasic low-grade nasopharyngeal papillary adenocarcinoma: a case report and literature review.","authors":"Hidenori Yokoi,&nbsp;Yuichi Terado,&nbsp;Masachika Fujiwara,&nbsp;Yuma Matsumoto,&nbsp;Tetsuya Ikeda,&nbsp;Koichiro Saito","doi":"10.1186/s12907-018-0076-1","DOIUrl":"https://doi.org/10.1186/s12907-018-0076-1","url":null,"abstract":"<p><strong>Background: </strong>Low-grade nasopharyngeal papillary adenocarcinoma (LGNPPA) is distinctly rare. We report a patient with a uniquely biphasic LGNPPA; additionally, we review similar tumors reported in the literature.</p><p><strong>Case presentation: </strong>A 56-year-old man presented with an asymptomatic pedunculated tumor in the vault of the nasopharynx, at the junction of the nasal septum and the roof, which was discovered during screening for laryngeal cancer. To obtain a definitive diagnosis, the patient underwent endoscopic endonasal surgery under general anesthesia. Immunohistochemical analysis of the tumor revealed it to be an LGNPPA with a prominent spindle cell component.</p><p><strong>Conclusion: </strong>To our knowledge, this is the fourth reported LGNPPA exhibiting a spindle cell component and the second with a prominent pathological condition. The prognosis of LGNPPA is usually excellent. Therefore, it is important for clinicians to scrutinize the lesion's pathology to avoid unnecessary, disfiguring surgery.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"18 ","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2018-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-018-0076-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36587460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer. p16和p53免疫组化表达在三阴性乳腺癌中的预后意义。
Q2 Medicine Pub Date : 2018-10-03 eCollection Date: 2018-01-01 DOI: 10.1186/s12907-018-0077-0
Atif Ali Hashmi, Samreen Naz, Shumaila Kanwal Hashmi, Zubaida Fida Hussain, Muhammad Irfan, Erum Yousuf Khan, Naveen Faridi, Amir Khan, Muhammad Muzzammil Edhi

Background: p16 and p53 genes are frequently mutated in triple negative breast cancer & prognostic value of these mutations have been shown; however, their role as immunohistochemical overexpression has not been fully validated. Therefore we aimed to evaluate the association of p16 and p53 overexpression in triple negative breast cancer with various prognostic parameters.

Methods: Total 150 cases of triple negative breast cancers were selected from records of pathology department archives that underwent surgeries at Liaquat National hospital, Karachi from January 2008 till December 2013. ER, PR and Her2neu immunohistochemistry were re-performed to confirm triple negative status. p16 & p53 immunohistochemistry was performed on all cases and association with various clinicopathologic parameters was determined.

Results: Mean age of the patients involved in the study was 48.9 years. Most of the patients presented at stage T2 with a high mean ki67 index i.e. 46.9%. 42.7% of cases had nodal metastasis. Although 84% cases were of invasive ductal carcinoma; however a significant proportion of cases were of metaplastic histology (9.3%). Fifty-one percent (76 cases) of cases showed positive p53 expression while 49% (74 cases) were negative. Higher percentage of p53 expression was found to correlate with higher T stage, high ki67 index and higher nodal stage. On the other hand, strong intensity of p53 expression was positively correlated with higher tumor grade and ki67 index. Seventy-one percent (98 cases) of cases showed positive p16 expression, whereas 24.8% (34 cases) were negative and 3.6% (5 cases) showed focal positive p16 expression. However, no significant association was found between p16 expression and various clinical and pathologic parameters. Similarly, no significant association of either p16 or p53 over-expression was noted with recurrence status of patients.

Conclusion: On the basis of significant association of p53 over-expression with worse prognostic factors in triple negative breast cancer, therefore we suggest that more large scale studies are needed to validate this finding in loco-regional population. Moreover, high expression of p16 in triple negative breast cancer suggests a potential role of this biomarker in triple negative breast cancer pathogenesis which should be investigated with molecular based research in our population.

背景:p16和p53基因在三阴性乳腺癌中经常发生突变,这些突变已被证明具有预后价值;然而,它们在免疫组织化学过表达中的作用尚未得到充分证实。因此,我们旨在评估p16和p53在三阴性乳腺癌中过表达与各种预后参数的关系。方法:选择2008年1月至2013年12月卡拉奇Liaquat国立医院病理科档案中收治的三阴性乳腺癌患者150例。再次行ER、PR、Her2neu免疫组化检查,确认三阴性。对所有病例进行P16和p53免疫组化,并确定与各种临床病理参数的关系。结果:参与研究的患者平均年龄为48.9岁。大多数患者出现在T2期,平均ki67指数较高,为46.9%。42.7%的病例有淋巴结转移。虽然84%为浸润性导管癌;然而,有相当比例的病例为化生组织学(9.3%)。51例(76例)p53表达阳性,49例(74例)p53表达阴性。高p53表达率与高T分期、高ki67指数和高淋巴结分期相关。另一方面,p53的高表达强度与较高的肿瘤分级和ki67指数呈正相关。p16阳性表达占71%(98例),阴性表达占24.8%(34例),局灶性阳性表达占3.6%(5例)。然而,p16的表达与各种临床和病理参数之间没有明显的关联。同样,p16或p53过表达与患者复发状态没有显著关联。结论:在三阴性乳腺癌中p53过表达与预后因素显著相关的基础上,我们建议需要更多的大规模研究来验证这一发现在局部区域人群中的有效性。此外,p16在三阴性乳腺癌中的高表达表明该生物标志物在三阴性乳腺癌发病机制中的潜在作用,应在我们的人群中进行基于分子的研究。
{"title":"Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer.","authors":"Atif Ali Hashmi,&nbsp;Samreen Naz,&nbsp;Shumaila Kanwal Hashmi,&nbsp;Zubaida Fida Hussain,&nbsp;Muhammad Irfan,&nbsp;Erum Yousuf Khan,&nbsp;Naveen Faridi,&nbsp;Amir Khan,&nbsp;Muhammad Muzzammil Edhi","doi":"10.1186/s12907-018-0077-0","DOIUrl":"https://doi.org/10.1186/s12907-018-0077-0","url":null,"abstract":"<p><strong>Background: </strong>p16 and p53 genes are frequently mutated in triple negative breast cancer & prognostic value of these mutations have been shown; however, their role as immunohistochemical overexpression has not been fully validated. Therefore we aimed to evaluate the association of p16 and p53 overexpression in triple negative breast cancer with various prognostic parameters.</p><p><strong>Methods: </strong>Total 150 cases of triple negative breast cancers were selected from records of pathology department archives that underwent surgeries at Liaquat National hospital, Karachi from January 2008 till December 2013. ER, PR and Her2neu immunohistochemistry were re-performed to confirm triple negative status. p16 & p53 immunohistochemistry was performed on all cases and association with various clinicopathologic parameters was determined.</p><p><strong>Results: </strong>Mean age of the patients involved in the study was 48.9 years. Most of the patients presented at stage T2 with a high mean ki67 index i.e. 46.9%. 42.7% of cases had nodal metastasis. Although 84% cases were of invasive ductal carcinoma; however a significant proportion of cases were of metaplastic histology (9.3%). Fifty-one percent (76 cases) of cases showed positive p53 expression while 49% (74 cases) were negative. Higher percentage of p53 expression was found to correlate with higher T stage, high ki67 index and higher nodal stage. On the other hand, strong intensity of p53 expression was positively correlated with higher tumor grade and ki67 index. Seventy-one percent (98 cases) of cases showed positive p16 expression, whereas 24.8% (34 cases) were negative and 3.6% (5 cases) showed focal positive p16 expression. However, no significant association was found between p16 expression and various clinical and pathologic parameters. Similarly, no significant association of either p16 or p53 over-expression was noted with recurrence status of patients.</p><p><strong>Conclusion: </strong>On the basis of significant association of p53 over-expression with worse prognostic factors in triple negative breast cancer, therefore we suggest that more large scale studies are needed to validate this finding in loco-regional population. Moreover, high expression of p16 in triple negative breast cancer suggests a potential role of this biomarker in triple negative breast cancer pathogenesis which should be investigated with molecular based research in our population.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"18 ","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2018-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-018-0077-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36572498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 27
Primary cutaneous nocardiosis: a diagnosis of consideration in a renal transplant recipient. 原发性皮肤诺卡病:肾移植受者的诊断考虑因素。
Q2 Medicine Pub Date : 2018-10-01 DOI: 10.1186/s12907-018-0075-2
Priyatam Khadka, Dibya Singh Shah

Background: The cutaneous nocardiosis remains a diagnostic challenge: similar clinical presentations as of cutaneous diseases with different etiology-and the inherent difficulty in cultivating the pathogen.

Case presentation: Herein, we describe a case of primary cutaneous nocardiosis in a renal transplant recipient; treated with anti-tubercular drugs due to misdiagnosis of cutaneous tuberculosis. On clinical examinations, a few red erythematous papules with erosions and crusting seen, over prior surgery scar of renal transplant. Multiple basophilic colonies surrounded by neutrophilic abscesses and granulation tissue were seen on histopathological examinations. The presumptive identification was done by Ziehl-neelson staining, bacterial culture, biochemical interpretations, and susceptibility pattern of the isolates to antibiotics. Radiographic imaging of brain and lungs were normal; no feature of disseminated nocardiosis seen. After 3 months of an anti-microbial therapy i.e. TMP-SMX(sulfamethoxazole and trimethoprim); the patient underwent progressive changes no relapse noted; transplant function observed in a good state, found asymptomatic with limited side effects on a regular follow up till now.

Conclusion: Cutaneous nocardiosis can occur in the renal-transplant patient. Therefore, a high degree of clinical suspicions, extensive clinical differentiation, early detection of the pathogen, apt selection of the antimicrobial therapy, correct dosing, and treatment duration is crucial for successful outcomes.

背景:皮肤诺卡病仍然是一个诊断挑战:与具有不同病因的皮肤疾病的临床表现相似,并且培养病原体的固有困难。病例介绍:在此,我们描述一例肾移植受者原发性皮肤诺卡病;由于皮肤结核的误诊,用抗结核药物治疗。临床检查,肾移植术前瘢痕上可见少量红色红斑丘疹,伴有糜烂和结痂。组织病理学检查发现多个嗜碱性集落被中性粒细胞脓肿和肉芽组织包围。通过Ziehl-neelson染色、细菌培养、生化解释和分离株对抗生素的易感性模式进行推定鉴定。脑、肺影像学检查正常;未见播散性诺卡病特征。在3个月的抗微生物治疗后,即TMP-SMX(磺胺甲恶唑和甲氧苄啶);患者经历了渐进性变化,未发现复发;移植功能观察良好,定期随访发现无症状,副作用有限。结论:肾移植患者可发生皮肤性诺卡病。因此,高度的临床怀疑、广泛的临床鉴别、病原体的早期检测、抗菌治疗的适当选择、正确的给药和治疗时间对成功的结果至关重要。
{"title":"Primary cutaneous nocardiosis: a diagnosis of consideration in a renal transplant recipient.","authors":"Priyatam Khadka,&nbsp;Dibya Singh Shah","doi":"10.1186/s12907-018-0075-2","DOIUrl":"10.1186/s12907-018-0075-2","url":null,"abstract":"<p><strong>Background: </strong>The cutaneous nocardiosis remains a diagnostic challenge: similar clinical presentations as of cutaneous diseases with different etiology-and the inherent difficulty in cultivating the pathogen.</p><p><strong>Case presentation: </strong>Herein, we describe a case of primary cutaneous nocardiosis in a renal transplant recipient; treated with anti-tubercular drugs due to misdiagnosis of cutaneous tuberculosis. On clinical examinations, a few red erythematous papules with erosions and crusting seen, over prior surgery scar of renal transplant. Multiple basophilic colonies surrounded by neutrophilic abscesses and granulation tissue were seen on histopathological examinations. The presumptive identification was done by Ziehl-neelson staining, bacterial culture, biochemical interpretations, and susceptibility pattern of the isolates to antibiotics. Radiographic imaging of brain and lungs were normal; no feature of disseminated nocardiosis seen. After 3 months of an anti-microbial therapy i.e. TMP-SMX(sulfamethoxazole and trimethoprim); the patient underwent progressive changes no relapse noted; transplant function observed in a good state, found asymptomatic with limited side effects on a regular follow up till now.</p><p><strong>Conclusion: </strong>Cutaneous nocardiosis can occur in the renal-transplant patient. Therefore, a high degree of clinical suspicions, extensive clinical differentiation, early detection of the pathogen, apt selection of the antimicrobial therapy, correct dosing, and treatment duration is crucial for successful outcomes.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"18 ","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-018-0075-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Diagnostic guidelines for the histological particle algorithm in the periprosthetic neo-synovial tissue. 组织学粒子算法在假体周围新滑膜组织中的诊断指南。
Q2 Medicine Pub Date : 2018-08-25 DOI: 10.1186/s12907-018-0074-3
G Perino, S Sunitsch, M Huber, D Ramirez, J Gallo, J Vaculova, S Natu, J P Kretzer, S Müller, P Thomas, M Thomsen, M G Krukemeyer, H Resch, T Hügle, W Waldstein, F Böettner, T Gehrke, S Sesselmann, W Rüther, Z Xia, E Purdue, V Krenn

Background: The identification of implant wear particles and non-implant related particles and the characterization of the inflammatory responses in the periprosthetic neo-synovial membrane, bone, and the synovial-like interface membrane (SLIM) play an important role for the evaluation of clinical outcome, correlation with radiological and implant retrieval studies, and understanding of the biological pathways contributing to implant failures in joint arthroplasty. The purpose of this study is to present a comprehensive histological particle algorithm (HPA) as a practical guide to particle identification at routine light microscopy examination.

Methods: The cases used for particle analysis were selected retrospectively from the archives of two institutions and were representative of the implant wear and non-implant related particle spectrum. All particle categories were described according to their size, shape, colour and properties observed at light microscopy, under polarized light, and after histochemical stains when necessary. A unified range of particle size, defined as a measure of length only, is proposed for the wear particles with five classes for polyethylene (PE) particles and four classes for conventional and corrosion metallic particles and ceramic particles.

Results: All implant wear and non-implant related particles were described and illustrated in detail by category. A particle scoring system for the periprosthetic tissue/SLIM is proposed as follows: 1) Wear particle identification at light microscopy with a two-step analysis at low (× 25, × 40, and × 100) and high magnification (× 200 and × 400); 2) Identification of the predominant wear particle type with size determination; 3) The presence of non-implant related endogenous and/or foreign particles. A guide for a comprehensive pathology report is also provided with sections for macroscopic and microscopic description, and diagnosis.

Conclusions: The HPA should be considered a standard for the histological analysis of periprosthetic neo-synovial membrane, bone, and SLIM. It provides a basic, standardized tool for the identification of implant wear and non-implant related particles at routine light microscopy examination and aims at reducing intra-observer and inter-observer variability to provide a common platform for multicentric implant retrieval/radiological/histological studies and valuable data for the risk assessment of implant performance for regional and national implant registries and government agencies.

背景:植入物磨损颗粒和非植入物相关颗粒的识别以及假体周围新滑膜、骨和滑膜样界面膜(SLIM)炎症反应的表征在评估临床结果、与放射学和植入物回收研究的相关性、,以及了解导致关节置换术中植入物失败的生物学途径。本研究的目的是提出一种全面的组织学颗粒算法(HPA),作为常规光学显微镜检查中颗粒识别的实用指南。方法:从两个机构的档案中回顾性选择用于颗粒分析的病例,这些病例具有植入物磨损和非植入物相关颗粒谱的代表性。根据在光学显微镜下、偏振光下以及必要时在组织化学染色后观察到的颗粒大小、形状、颜色和特性,对所有颗粒类别进行了描述。提出了磨损颗粒的统一粒径范围,仅定义为长度测量,聚乙烯(PE)颗粒有五类,传统和腐蚀金属颗粒和陶瓷颗粒有四类。结果:按类别详细描述和说明了所有植入物磨损和非植入物相关颗粒。提出了一种假体周围组织/SIM的颗粒评分系统:1)在光学显微镜下进行磨损颗粒识别,在低(×25、×40和×100)和高放大率(×200和×400)下进行两步分析;2) 通过尺寸测定确定主要磨损颗粒类型;3) 存在与植入物无关的内源性和/或外来颗粒。综合病理学报告的指南也提供了宏观和微观描述以及诊断的章节。结论:HPA应被视为假体周围新滑膜、骨和SLIM组织学分析的标准。它提供了一种基本的,用于在常规光学显微镜检查中识别植入物磨损和非植入物相关颗粒的标准化工具,旨在减少观察者内部和观察者之间的差异,为多中心植入物检索/放射学/组织学研究提供一个通用平台,并为区域和国家植入物植入物性能的风险评估提供有价值的数据登记处和政府机构。
{"title":"Diagnostic guidelines for the histological particle algorithm in the periprosthetic neo-synovial tissue.","authors":"G Perino,&nbsp;S Sunitsch,&nbsp;M Huber,&nbsp;D Ramirez,&nbsp;J Gallo,&nbsp;J Vaculova,&nbsp;S Natu,&nbsp;J P Kretzer,&nbsp;S Müller,&nbsp;P Thomas,&nbsp;M Thomsen,&nbsp;M G Krukemeyer,&nbsp;H Resch,&nbsp;T Hügle,&nbsp;W Waldstein,&nbsp;F Böettner,&nbsp;T Gehrke,&nbsp;S Sesselmann,&nbsp;W Rüther,&nbsp;Z Xia,&nbsp;E Purdue,&nbsp;V Krenn","doi":"10.1186/s12907-018-0074-3","DOIUrl":"10.1186/s12907-018-0074-3","url":null,"abstract":"<p><strong>Background: </strong>The identification of implant wear particles and non-implant related particles and the characterization of the inflammatory responses in the periprosthetic neo-synovial membrane, bone, and the synovial-like interface membrane (SLIM) play an important role for the evaluation of clinical outcome, correlation with radiological and implant retrieval studies, and understanding of the biological pathways contributing to implant failures in joint arthroplasty. The purpose of this study is to present a comprehensive histological particle algorithm (HPA) as a practical guide to particle identification at routine light microscopy examination.</p><p><strong>Methods: </strong>The cases used for particle analysis were selected retrospectively from the archives of two institutions and were representative of the implant wear and non-implant related particle spectrum. All particle categories were described according to their size, shape, colour and properties observed at light microscopy, under polarized light, and after histochemical stains when necessary. A unified range of particle size, defined as a measure of length only, is proposed for the wear particles with five classes for polyethylene (PE) particles and four classes for conventional and corrosion metallic particles and ceramic particles.</p><p><strong>Results: </strong>All implant wear and non-implant related particles were described and illustrated in detail by category. A particle scoring system for the periprosthetic tissue/SLIM is proposed as follows: 1) Wear particle identification at light microscopy with a two-step analysis at low (× 25, × 40, and × 100) and high magnification (× 200 and × 400); 2) Identification of the predominant wear particle type with size determination; 3) The presence of non-implant related endogenous and/or foreign particles. A guide for a comprehensive pathology report is also provided with sections for macroscopic and microscopic description, and diagnosis.</p><p><strong>Conclusions: </strong>The HPA should be considered a standard for the histological analysis of periprosthetic neo-synovial membrane, bone, and SLIM. It provides a basic, standardized tool for the identification of implant wear and non-implant related particles at routine light microscopy examination and aims at reducing intra-observer and inter-observer variability to provide a common platform for multicentric implant retrieval/radiological/histological studies and valuable data for the risk assessment of implant performance for regional and national implant registries and government agencies.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"18 ","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2018-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-018-0074-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36439552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 24
Diagnostic pitfall: primary myoepithelial carcinoma of the lacrimal gland, case report and literature review. 诊断缺陷:原发性泪腺肌上皮癌,病例报告及文献复习。
Q2 Medicine Pub Date : 2018-08-02 eCollection Date: 2018-01-01 DOI: 10.1186/s12907-018-0073-4
Youssef Mahdi, Mohamed Amine Azami, Rajae Daoudi, Nadia Cherradi

Background: In lacrimal gland, lymphomas and inflammatory lesions predominate. Primary epithelial tumours represent less than 30% of lacrimal gland lesions. Myoepithelial carcinoma of lacrimal gland is rare. To the best of our knowledge, only nine cases have been reported in the literature. This lesion presents diagnostic difficulties: non-specific clinical and radiological findings and histological polymorphism. This is well illustrated by the diagnostic pathology errors described in the literature.We report a new case of lacrimal myoepithelial carcinoma with a review of others published cases to try to assess clinico-pathological features and outcome whenever possible of this rare tumour.

Case presentation: An 80-year-old Arabian female presented with a 2-month history of swelling over the right eyebrow, pain, proptosis of the right eye and diplopia. Computed tomography demonstrated an ill-defined, homogeneous, contrast-enhancing mass attached to the medial rectus. A biopsy was performed. Microscopic examination showed malignant spindle cells tumour, most consistently to sarcoma or sarcomatoid carcinoma. Immunohistochemical study was not possible because neoplastic material has been exhausted. Subsequently, total exenteration of the right orbit was performed. Immunohistochemical study revealed diffuse positive staining for pancytokeratin AE1/AE3, epithelial membrane antigen (EMA) and smooth muscle actin (SMA) and focal positivity for S100 protein. The lesion was immunonegative for desmin, h-cladesmon, CD34, Melan-A and HMB-45. The tumour was extending to the surgical margins. The patient was lost to follow-up until she developed local tumour progression 3 months after removal. The patient was again lost to follow-up and therefore did not receive any other treatment in our hospital.

Conclusion: We present this rare tumour with an unusual location. The use of a complete immunohistochemical panel with epithelial and myoepithelial markers positivity helped us for classification of this poorly differentiated tumour.

背景:泪腺以淋巴瘤和炎性病变为主。原发性上皮肿瘤占不到30%的泪腺病变。泪腺肌上皮癌是罕见的。据我们所知,文献中只报道了9例。这种病变呈现诊断困难:非特异性临床和放射学表现和组织学多态性。这很好地说明了在文献中描述的诊断病理错误。我们报告一例新的泪腺肌上皮癌,并回顾其他已发表的病例,试图评估这种罕见肿瘤的临床病理特征和预后。病例介绍:一名80岁阿拉伯女性,右眉肿胀、疼痛、右眼突出和复视2个月。计算机断层扫描显示一模糊、均匀、增强对比度的肿块附着于内侧直肌。进行了活检。镜下检查为恶性梭形细胞瘤,与肉瘤或肉瘤样癌最一致。由于肿瘤材料已经耗尽,免疫组化研究无法进行。随后,行右眼眶全切除术。免疫组化结果显示,全细胞角蛋白AE1/AE3、上皮膜抗原(EMA)、平滑肌肌动蛋白(SMA)弥漫性阳性,S100蛋白局灶性阳性。病变对desmin、h-cladesmon、CD34、Melan-A和HMB-45均呈免疫阴性。肿瘤已扩散到手术边缘。患者在切除手术3个月后出现局部肿瘤进展,才开始随访。患者再次失去随访,因此未在我院接受任何其他治疗。结论:我们报告了一个罕见的肿瘤,其位置不寻常。使用上皮和肌上皮标志物阳性的完整免疫组织化学小组帮助我们对这种低分化肿瘤进行分类。
{"title":"Diagnostic pitfall: primary myoepithelial carcinoma of the lacrimal gland, case report and literature review.","authors":"Youssef Mahdi,&nbsp;Mohamed Amine Azami,&nbsp;Rajae Daoudi,&nbsp;Nadia Cherradi","doi":"10.1186/s12907-018-0073-4","DOIUrl":"https://doi.org/10.1186/s12907-018-0073-4","url":null,"abstract":"<p><strong>Background: </strong>In lacrimal gland, lymphomas and inflammatory lesions predominate. Primary epithelial tumours represent less than 30% of lacrimal gland lesions. Myoepithelial carcinoma of lacrimal gland is rare. To the best of our knowledge, only nine cases have been reported in the literature. This lesion presents diagnostic difficulties: non-specific clinical and radiological findings and histological polymorphism. This is well illustrated by the diagnostic pathology errors described in the literature.We report a new case of lacrimal myoepithelial carcinoma with a review of others published cases to try to assess clinico-pathological features and outcome whenever possible of this rare tumour.</p><p><strong>Case presentation: </strong>An 80-year-old Arabian female presented with a 2-month history of swelling over the right eyebrow, pain, proptosis of the right eye and diplopia. Computed tomography demonstrated an ill-defined, homogeneous, contrast-enhancing mass attached to the medial rectus. A biopsy was performed. Microscopic examination showed malignant spindle cells tumour, most consistently to sarcoma or sarcomatoid carcinoma. Immunohistochemical study was not possible because neoplastic material has been exhausted. Subsequently, total exenteration of the right orbit was performed. Immunohistochemical study revealed diffuse positive staining for pancytokeratin AE1/AE3, epithelial membrane antigen (EMA) and smooth muscle actin (SMA) and focal positivity for S100 protein. The lesion was immunonegative for desmin, h-cladesmon, CD34, Melan-A and HMB-45. The tumour was extending to the surgical margins. The patient was lost to follow-up until she developed local tumour progression 3 months after removal. The patient was again lost to follow-up and therefore did not receive any other treatment in our hospital.</p><p><strong>Conclusion: </strong>We present this rare tumour with an unusual location. The use of a complete immunohistochemical panel with epithelial and myoepithelial markers positivity helped us for classification of this poorly differentiated tumour.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"18 ","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2018-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-018-0073-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36409776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
B-chronic lymphocytic leukemia showed triple transformation, to diffuse large B cell, CD20-negative, and T-cell neoplasm during ofatumumab treatment: a case report. B-慢性淋巴细胞白血病在ofatumumab治疗期间显示三重转化,弥漫性大B细胞、cd20阴性和t细胞肿瘤:1例报告。
Q2 Medicine Pub Date : 2018-05-22 eCollection Date: 2018-01-01 DOI: 10.1186/s12907-018-0072-5
Osamu Imataki, Makiko Uemura

Background: Chronic lymphocytic leukemia (CLL) is a mature lymphoid neoplasm currently categorized as an indolent type of malignant lymphoma. CLL progresses slowly over years, but it eventually transforms to a more aggressive lymphoma such as the diffuse large B-cell (DLBCL) type, also known as Richter's syndrome.

Case presentation: We treated a 69-year-old Japanese male who was histologically diagnosed with Richter's syndrome after 6 years of CLL. His lymphadenopathy had systemically progressed for years, with lymphocyte counts of less than 10,000 cells/μL and a disease status of Rai classification stage I and Binet classification B. He had high fever and hepatosplenomegaly upon Richter's transformation. The patient was treated with ofatumumab for refractory CLL, which relieved his febrile lymphadenopathy. He received a total of 11 ofatumumab courses and achieved partial remission. On the day of the 12th course of ofatumumab, his disease relapsed with febrile lymphadenopathy. Computed tomography revealed multiple liver masses and systemic lymphadenopathy, while a liver biopsy confirmed T-cell lymphoma. Concomitantly, CD20-lacking CLL cells were detected in his peripheral blood and bone marrow, and pathological examination of his left cervical lymph node biopsy showed CD20-positive DLBCL. The final diagnosis was three different types of lymphoma pathologies: (1) CD20-positive DLBCL of the lymph nodes, (2) CD20-lacking CLL of the peripheral blood and bone marrow, and (3) peripheral T-cell lymphoma (PTCL) of the liver. He received intravenous and oral dexamethasone therapy as palliative care. He died because of the rapid progression of abdominal masses 2 months after the diagnosis of triple transformation CLL. An autopsy revealed aggressive PTCL with aggressive systemic involvement of the liver, spleen, gall bladder, pericardium, bone marrow, and mediastinal-paraaortic-intraceliac lymph nodes. T-cell receptor study of an autopsy specimen supported the diagnosis of PTCL that spread to the intraceliac organs and lymph nodes. We concluded that his pathogenicity progressed to a mixture of triple lymphoma as a result of double malignant transformations, which included PTCL from CLL, CD20-negative CLL, and CD20-positive DLBCL by Richter's transformation.

Conclusions: Our case provides information on the biology of CLL, to transform from a low-grade chemosensitive status to a malignant chemoresistant status.

背景:慢性淋巴细胞白血病(CLL)是一种成熟的淋巴样肿瘤,目前被归类为惰性型恶性淋巴瘤。慢性淋巴细胞白血病进展缓慢,但最终会转变为更具侵袭性的淋巴瘤,如弥漫性大b细胞(DLBCL)型,也称为Richter综合征。病例介绍:我们治疗了一位69岁的日本男性,他在6年的慢性淋巴细胞白血病后被组织学诊断为里希特综合征。淋巴结病变全系统进展多年,淋巴细胞计数小于1万个/μL, Rai分级I期和Binet分级b期,Richter转化后出现高热、肝脾肿大。患者接受了ofatumumab治疗难治性CLL,缓解了他的发热性淋巴结病。他总共接受了11个ofatumumab疗程,并获得部分缓解。在第12个疗程的当天,他的疾病复发并伴有发热性淋巴结病。计算机断层扫描显示多发性肝脏肿块和全身性淋巴结病,而肝脏活检证实t细胞淋巴瘤。同时,外周血和骨髓中检测到cd20缺失的CLL细胞,左颈淋巴结活检病理检查显示cd20阳性DLBCL。最终诊断为三种不同类型的淋巴瘤病理:(1)淋巴结cd20阳性的DLBCL,(2)外周血和骨髓缺乏cd20的CLL,(3)肝脏外周t细胞淋巴瘤(PTCL)。他接受静脉和口服地塞米松治疗作为姑息治疗。他在诊断为三转化CLL后2个月因腹部肿块迅速发展而死亡。尸检显示侵袭性PTCL伴侵袭性全身累及肝脏、脾脏、胆囊、心包、骨髓和纵隔-腹主动脉旁-腹腔内淋巴结。尸检标本的t细胞受体研究支持PTCL扩散到腹腔内器官和淋巴结的诊断。我们的结论是,由于双重恶性转化,其致病性发展为三重淋巴瘤的混合物,包括CLL的PTCL, cd20阴性CLL和cd20阳性DLBCL的Richter转化。结论:我们的病例提供了CLL从低度化疗敏感状态转变为恶性化疗耐药状态的生物学信息。
{"title":"B-chronic lymphocytic leukemia showed triple transformation, to diffuse large B cell, CD20-negative, and T-cell neoplasm during ofatumumab treatment: a case report.","authors":"Osamu Imataki,&nbsp;Makiko Uemura","doi":"10.1186/s12907-018-0072-5","DOIUrl":"https://doi.org/10.1186/s12907-018-0072-5","url":null,"abstract":"<p><strong>Background: </strong>Chronic lymphocytic leukemia (CLL) is a mature lymphoid neoplasm currently categorized as an indolent type of malignant lymphoma. CLL progresses slowly over years, but it eventually transforms to a more aggressive lymphoma such as the diffuse large B-cell (DLBCL) type, also known as Richter's syndrome.</p><p><strong>Case presentation: </strong>We treated a 69-year-old Japanese male who was histologically diagnosed with Richter's syndrome after 6 years of CLL. His lymphadenopathy had systemically progressed for years, with lymphocyte counts of less than 10,000 cells/μL and a disease status of Rai classification stage I and Binet classification B. He had high fever and hepatosplenomegaly upon Richter's transformation. The patient was treated with ofatumumab for refractory CLL, which relieved his febrile lymphadenopathy. He received a total of 11 ofatumumab courses and achieved partial remission. On the day of the 12th course of ofatumumab, his disease relapsed with febrile lymphadenopathy. Computed tomography revealed multiple liver masses and systemic lymphadenopathy, while a liver biopsy confirmed T-cell lymphoma. Concomitantly, CD20-lacking CLL cells were detected in his peripheral blood and bone marrow, and pathological examination of his left cervical lymph node biopsy showed CD20-positive DLBCL. The final diagnosis was three different types of lymphoma pathologies: (1) CD20-positive DLBCL of the lymph nodes, (2) CD20-lacking CLL of the peripheral blood and bone marrow, and (3) peripheral T-cell lymphoma (PTCL) of the liver. He received intravenous and oral dexamethasone therapy as palliative care. He died because of the rapid progression of abdominal masses 2 months after the diagnosis of triple transformation CLL. An autopsy revealed aggressive PTCL with aggressive systemic involvement of the liver, spleen, gall bladder, pericardium, bone marrow, and mediastinal-paraaortic-intraceliac lymph nodes. T-cell receptor study of an autopsy specimen supported the diagnosis of PTCL that spread to the intraceliac organs and lymph nodes. We concluded that his pathogenicity progressed to a mixture of triple lymphoma as a result of double malignant transformations, which included PTCL from CLL, CD20-negative CLL, and CD20-positive DLBCL by Richter's transformation.</p><p><strong>Conclusions: </strong>Our case provides information on the biology of CLL, to transform from a low-grade chemosensitive status to a malignant chemoresistant status.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"18 ","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2018-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-018-0072-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36127564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Evaluation of SD BIOLINE H. pylori Ag rapid test against double ELISA with SD H. pylori Ag ELISA and EZ-STEP H. pylori Ag ELISA tests. SD BIOLINE幽门螺杆菌抗原快速检测与SD幽门螺杆菌抗原ELISA和EZ-STEP幽门螺杆菌抗原ELISA双酶联免疫吸附试验的比较
Q2 Medicine Pub Date : 2018-03-05 eCollection Date: 2018-01-01 DOI: 10.1186/s12907-018-0071-6
Markos Negash, Afework Kassu, Bemnet Amare, Gizachew Yismaw, Beyene Moges

Background: Helicobacter pylori antibody titters fall very slowly even after successful treatment. Therefore, tests detecting H. pylori antibody lack specificity and sensitivity. On the other hand, H. pylori stool antigen tests are reported as an alternative assay because of their reliability and simplicity. However, the comparative performance of H. pylori stool antigen tests for detecting the presence of the bacterium in clinical specimens in the study area is not assessed. Therefore, in this study we evaluated the performance of SD BIOLINE H. pylori Ag rapid test with reference to the commercially available EZ- STEP ELISA and SD BIOLINE H. pylori Ag ELISA tests.

Methods: Stool samples were collected to analyse the diagnostic performance of SD BIOLINE H. pylori Ag rapid test kit using SD H. pylori Ag ELISA kit and EZ- STEP ELISA tests as a gold standard. Serum samples were also collected from each patient to test for the presence of H. pylori antibodies using dBest H. pylori Test Disk. Sensitivity, specificity, predictive values and kappa value are assessed. P values < 0.05 were taken statistically significant.

Results: Stool and serum samples were collected from 201 dyspeptic patients and analysed. The sensitivity, specificity, positive and negative predictive values of the SD BIOLINE H. pylori Ag rapid test were: 95.6% (95% CI, 88.8-98.8), 92.5% (95%CI, 89-94.1%), 86.7% (95% CI, 80.5-89.6), and 97.6% (95% CI, 993.9-99.3) respectively.

Conclusion: The performance of SD BIOLINE H. pylori Ag rapid test was better than the currently available antibody test in study area. Therefore, the SD BIOLINE Ag rapid stool test could replace and be used to diagnose active H. pylori infection before the commencement of therapy among dyspeptic patients.

背景:即使治疗成功,幽门螺杆菌抗体滴度也会缓慢下降。因此,检测幽门螺杆菌抗体的方法缺乏特异性和敏感性。另一方面,幽门螺杆菌粪便抗原检测由于其可靠性和简单性被报道为一种替代检测方法。然而,在研究地区的临床标本中,幽门螺杆菌粪便抗原检测检测细菌存在的比较性能没有得到评估。因此,在本研究中,我们参考市售的EZ- STEP ELISA和SD BIOLINE幽门螺杆菌抗原ELISA检测来评估SD BIOLINE幽门螺杆菌抗原快速检测的性能。方法:收集粪便标本,以SD幽门螺杆菌抗原酶联免疫吸附测定试剂盒和EZ- STEP酶联免疫吸附测定试剂盒为金标准,分析SD BIOLINE幽门螺杆菌抗原快速检测试剂盒的诊断效果。同时采集每位患者的血清样本,使用dBest幽门螺杆菌检测盘检测是否存在幽门螺杆菌抗体。评估敏感性、特异性、预测值和kappa值。结果:对201例消化不良患者的粪便和血清进行分析。SD BIOLINE幽门螺杆菌抗原快速检测的敏感性、特异性、阳性预测值和阴性预测值分别为95.6% (95%CI, 88.8 ~ 98.8)、92.5% (95%CI, 89 ~ 94.1%)、86.7% (95%CI, 80.5 ~ 89.6)和97.6% (95%CI, 993.9 ~ 99.3)。结论:SD BIOLINE幽门螺杆菌抗原快速检测方法的检测效果优于研究地区现有的抗体检测方法。因此,SD BIOLINE Ag快速大便试验可替代并用于消化不良患者开始治疗前诊断活动性幽门螺杆菌感染。
{"title":"Evaluation of SD BIOLINE <i>H. pylori</i> Ag rapid test against double ELISA with SD <i>H. pylori</i> Ag ELISA and EZ-STEP <i>H. pylori</i> Ag ELISA tests.","authors":"Markos Negash,&nbsp;Afework Kassu,&nbsp;Bemnet Amare,&nbsp;Gizachew Yismaw,&nbsp;Beyene Moges","doi":"10.1186/s12907-018-0071-6","DOIUrl":"https://doi.org/10.1186/s12907-018-0071-6","url":null,"abstract":"<p><strong>Background: </strong><i>Helicobacter pylori</i> antibody titters fall very slowly even after successful treatment. Therefore, tests detecting <i>H. pylori</i> antibody lack specificity and sensitivity. On the other hand, <i>H. pylori</i> stool antigen tests are reported as an alternative assay because of their reliability and simplicity. However, the comparative performance of <i>H. pylori</i> stool antigen tests for detecting the presence of the bacterium in clinical specimens in the study area is not assessed. Therefore, in this study we evaluated the performance of SD BIOLINE <i>H. pylori</i> Ag rapid test with reference to the commercially available EZ- STEP ELISA and SD BIOLINE <i>H. pylori</i> Ag ELISA tests.</p><p><strong>Methods: </strong>Stool samples were collected to analyse the diagnostic performance of SD BIOLINE <i>H. pylori</i> Ag rapid test kit using SD <i>H. pylori</i> Ag ELISA kit and EZ- STEP ELISA tests as a gold standard. Serum samples were also collected from each patient to test for the presence of <i>H. pylori</i> antibodies using dBest <i>H. pylori</i> Test Disk. Sensitivity, specificity, predictive values and kappa value are assessed. <i>P</i> values < 0.05 were taken statistically significant.</p><p><strong>Results: </strong>Stool and serum samples were collected from 201 dyspeptic patients and analysed. The sensitivity, specificity, positive and negative predictive values of the SD BIOLINE <i>H. pylori</i> Ag rapid test were: 95.6% (95% CI, 88.8-98.8), 92.5% (95%CI, 89-94.1%), 86.7% (95% CI, 80.5-89.6), and 97.6% (95% CI, 993.9-99.3) respectively.</p><p><strong>Conclusion: </strong>The performance of SD BIOLINE <i>H. pylori</i> Ag rapid test was better than the currently available antibody test in study area. Therefore, the SD BIOLINE Ag rapid stool test could replace and be used to diagnose active <i>H. pylori</i> infection before the commencement of therapy among dyspeptic patients.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"18 ","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2018-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-018-0071-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35893238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Primary hepatic neuroendocrine carcinoma: report of two cases and literature review. 原发性肝脏神经内分泌癌2例报告并文献复习。
Q2 Medicine Pub Date : 2018-03-01 eCollection Date: 2018-01-01 DOI: 10.1186/s12907-018-0070-7
Zi-Ming Zhao, Jin Wang, Ugochukwu C Ugwuowo, Liming Wang, Jeffrey P Townsend

Background: Primary hepatic neuroendocrine carcinoma (PHNEC) is extremely rare. The diagnosis of PHNEC remains challenging-partly due to its rarity, and partly due to its lack of unique clinical features. Available treatment options for PHNEC include surgical resection of the liver tumor(s), radiotherapy, liver transplant, transcatheter arterial chemoembolization (TACE), and administration of somatostatin analogues.

Case presentation: We report two male PHNEC cases and discuss the diagnosis and treatment options. Both cases presented with abdominal pain; case two also presented with symptoms of jaundice. The initial diagnosis for both cases was poorly differentiated grade 3 small-cell neuroendocrine carcinoma, based on imaging characteristics and the pathology of liver biopsies. Final diagnoses of PHNEC were arrived at by ruling out non-hepatic origins. Case one presented with a large tumor in the right liver lobe, and the patient was treated with TACE. Case two presented with tumors in both liver lobes, invasions into the left branch of hepatic portal vein, and metastasis in the hepatic hilar lymph node. This patient was ineligible for TACE and was allergic to the somatostatin analogue octreotide. This limited treatment options to supportive therapies such as albumin supplementation for liver protection. Patient one and two died at 61 and 109 days, respectively, following initial hospital admission.

Conclusions: We diagnosed both cases with poorly differentiated grade 3 small-cell PHNEC through imaging characteristics, immunohistochemical staining of liver biopsies, and examinations to eliminate non-hepatic origins. Neither TACE nor liver protection appeared to significantly extend survival time of the two patients, suggesting these treatments may be inadequate to improve survival of patients with poorly differentiated grade 3 small-cell PHNEC. The prognosis of poorly differentiated grade 3 small-cell PHNEC is poor due to limited and ineffective treatment options.

背景:原发性肝神经内分泌癌(PHNEC)极为罕见。PHNEC的诊断仍然具有挑战性,部分原因是其罕见,部分原因是其缺乏独特的临床特征。PHNEC可用的治疗方案包括肝肿瘤手术切除、放疗、肝移植、经导管动脉化疗栓塞(TACE)和给予生长抑素类似物。病例介绍:我们报告两例男性PHNEC病例,并讨论诊断和治疗方案。两例均表现为腹痛;病例2也有黄疸症状。根据影像学特征和肝活检病理,两例患者的初步诊断均为低分化3级小细胞神经内分泌癌。PHNEC的最终诊断是通过排除非肝脏来源得出的。病例1为右肝叶大肿瘤,经TACE治疗。病例二表现为双肝叶肿瘤,侵犯肝门静脉左支,肝门淋巴结转移。该患者不适合接受TACE治疗,并且对生长抑素类似物奥曲肽过敏。这限制了支持治疗的选择,如补充白蛋白以保护肝脏。患者1和患者2分别在初次入院后61天和109天死亡。结论:我们通过影像学特征、肝活检免疫组化染色和排除非肝脏来源的检查,诊断这两例为低分化3级小细胞PHNEC。TACE和肝脏保护均未显着延长两例患者的生存时间,提示这些治疗可能不足以提高低分化3级小细胞PHNEC患者的生存。低分化3级小细胞PHNEC由于治疗方案有限且无效,预后较差。
{"title":"Primary hepatic neuroendocrine carcinoma: report of two cases and literature review.","authors":"Zi-Ming Zhao,&nbsp;Jin Wang,&nbsp;Ugochukwu C Ugwuowo,&nbsp;Liming Wang,&nbsp;Jeffrey P Townsend","doi":"10.1186/s12907-018-0070-7","DOIUrl":"https://doi.org/10.1186/s12907-018-0070-7","url":null,"abstract":"<p><strong>Background: </strong>Primary hepatic neuroendocrine carcinoma (PHNEC) is extremely rare. The diagnosis of PHNEC remains challenging-partly due to its rarity, and partly due to its lack of unique clinical features. Available treatment options for PHNEC include surgical resection of the liver tumor(s), radiotherapy, liver transplant, transcatheter arterial chemoembolization (TACE), and administration of somatostatin analogues.</p><p><strong>Case presentation: </strong>We report two male PHNEC cases and discuss the diagnosis and treatment options. Both cases presented with abdominal pain; case two also presented with symptoms of jaundice. The initial diagnosis for both cases was poorly differentiated grade 3 small-cell neuroendocrine carcinoma, based on imaging characteristics and the pathology of liver biopsies. Final diagnoses of PHNEC were arrived at by ruling out non-hepatic origins. Case one presented with a large tumor in the right liver lobe, and the patient was treated with TACE. Case two presented with tumors in both liver lobes, invasions into the left branch of hepatic portal vein, and metastasis in the hepatic hilar lymph node. This patient was ineligible for TACE and was allergic to the somatostatin analogue octreotide. This limited treatment options to supportive therapies such as albumin supplementation for liver protection. Patient one and two died at 61 and 109 days, respectively, following initial hospital admission.</p><p><strong>Conclusions: </strong>We diagnosed both cases with poorly differentiated grade 3 small-cell PHNEC through imaging characteristics, immunohistochemical staining of liver biopsies, and examinations to eliminate non-hepatic origins. Neither TACE nor liver protection appeared to significantly extend survival time of the two patients, suggesting these treatments may be inadequate to improve survival of patients with poorly differentiated grade 3 small-cell PHNEC. The prognosis of poorly differentiated grade 3 small-cell PHNEC is poor due to limited and ineffective treatment options.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"18 ","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-018-0070-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35885834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 22
The expression of MDM2 in gastrointestinal stromal tumors: immunohistochemical analysis of 35 cases. 35例胃肠道间质瘤中MDM2表达的免疫组化分析。
Q2 Medicine Pub Date : 2018-01-24 eCollection Date: 2018-01-01 DOI: 10.1186/s12907-018-0069-0
Boubacar Efared, Gabrielle Atsame-Ebang, Layla Tahiri, Ibrahim Sory Sidibé, Fatimazahra Erregad, Nawal Hammas, Samia Arifi, Ihsane Mellouki, Abdelmalek Ousadden, Khalid Mazaz, Hinde El Fatemi, Laila Chbani

Background: Gastrointestinal stromal tumors (GIST) are the most common primary mesenchymal tumors of the digestive system. The assessment of their biological behavior still remains a scientific challenge. To date, there are no well-established biological prognostic markers of GIST. Our aim is to study the expression of the MDM2 oncoprotein in GIST through an immunohistochemical analysis.

Methods: It was a retrospective study of 35 cases of GIST diagnosed from 2009 to 2012 in the department of pathology of Hassan II university hospital, Fès, Morocco. MDM2 immunohistochemical staining was performed on archival paraffin-embedded and formalin-fixed specimens (with a threshold of nuclear positivity > 10%). Analysis of correlations between MDM2 immunoexpression and clinicopathological features of GIST has been performed.

Results: The mean age was 55.23 years (range 25-84 years) with a male predominance (sex ratio = 1.5). The stomach was the main site of GIST, with 17 cases (48.57%) followed by the small bowel (9 cases, 25.71%). The spindle cell type GIST was the most frequent morphological variant (29 cases, 82.85%). Tumor necrosis was present in 8 cases (22.85%). Two patients (5.71%) had very low risk GIST, 5 (14.28%) had low risk GIST, 7 patients (20%) had intermediate risk tumors. The remaining 21 cases (60%) had high risk GIST. At the time of diagnosis, 9 patients (25.71%) had metastatic tumors. At immunohistochemical analysis, 40% of cases (14 patients) stained positive for MDM2. Of these MDMD2-positive tumors, 11/14 (78.57%) had high risk tumors and 8/14 cases (57.14%) presented with metastatic GIST. MDM2 positivity was significantly associated with the metastatic status (p = 0.001).

Conclusion: The current study suggests that MDM2 immunohistochemical expression is a negative histoprognostic factor in GIST with a statistically significant correlation with metastasis.

背景:胃肠道间质瘤(GIST)是消化道最常见的原发性间质肿瘤。对它们的生物学行为的评估仍然是一个科学挑战。迄今为止,还没有明确的GIST生物学预后标志物。我们的目的是通过免疫组织化学分析研究MDM2癌蛋白在GIST中的表达。方法:对2009 ~ 2012年在摩洛哥f市哈桑二世大学医院病理科诊断的35例GIST患者进行回顾性分析。对档案石蜡包埋和福尔马林固定标本(核阳性阈值> 10%)进行MDM2免疫组化染色。分析了MDM2免疫表达与GIST临床病理特征之间的相关性。结果:平均年龄55.23岁(25 ~ 84岁),男性居多(性别比为1.5)。胃肠道间质瘤以胃为主要部位,17例(48.57%),其次为小肠(9例,25.71%)。以梭形细胞型GIST最常见(29例,82.85%)。肿瘤坏死8例(22.85%)。极低危GIST 2例(5.71%),低危GIST 5例(14.28%),中危肿瘤7例(20%)。其余21例(60%)为高危GIST。确诊时有转移性肿瘤9例(25.71%)。免疫组化分析显示,40%的病例(14例)MDM2染色阳性。在这些mdmd2阳性肿瘤中,11/14(78.57%)为高危肿瘤,8/14(57.14%)为转移性GIST。MDM2阳性与转移状态显著相关(p = 0.001)。结论:本研究提示MDM2免疫组化表达是GIST的阴性组织预后因素,与转移有统计学意义。
{"title":"The expression of MDM2 in gastrointestinal stromal tumors: immunohistochemical analysis of 35 cases.","authors":"Boubacar Efared,&nbsp;Gabrielle Atsame-Ebang,&nbsp;Layla Tahiri,&nbsp;Ibrahim Sory Sidibé,&nbsp;Fatimazahra Erregad,&nbsp;Nawal Hammas,&nbsp;Samia Arifi,&nbsp;Ihsane Mellouki,&nbsp;Abdelmalek Ousadden,&nbsp;Khalid Mazaz,&nbsp;Hinde El Fatemi,&nbsp;Laila Chbani","doi":"10.1186/s12907-018-0069-0","DOIUrl":"https://doi.org/10.1186/s12907-018-0069-0","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal stromal tumors (GIST) are the most common primary mesenchymal tumors of the digestive system. The assessment of their biological behavior still remains a scientific challenge. To date, there are no well-established biological prognostic markers of GIST. Our aim is to study the expression of the MDM2 oncoprotein in GIST through an immunohistochemical analysis.</p><p><strong>Methods: </strong>It was a retrospective study of 35 cases of GIST diagnosed from 2009 to 2012 in the department of pathology of Hassan II university hospital, Fès, Morocco. MDM2 immunohistochemical staining was performed on archival paraffin-embedded and formalin-fixed specimens (with a threshold of nuclear positivity > 10%). Analysis of correlations between MDM2 immunoexpression and clinicopathological features of GIST has been performed.</p><p><strong>Results: </strong>The mean age was 55.23 years (range 25-84 years) with a male predominance (sex ratio = 1.5). The stomach was the main site of GIST, with 17 cases (48.57%) followed by the small bowel (9 cases, 25.71%). The spindle cell type GIST was the most frequent morphological variant (29 cases, 82.85%). Tumor necrosis was present in 8 cases (22.85%). Two patients (5.71%) had very low risk GIST, 5 (14.28%) had low risk GIST, 7 patients (20%) had intermediate risk tumors. The remaining 21 cases (60%) had high risk GIST. At the time of diagnosis, 9 patients (25.71%) had metastatic tumors. At immunohistochemical analysis, 40% of cases (14 patients) stained positive for MDM2. Of these MDMD2-positive tumors, 11/14 (78.57%) had high risk tumors and 8/14 cases (57.14%) presented with metastatic GIST. MDM2 positivity was significantly associated with the metastatic status (<i>p</i> = 0.001).</p><p><strong>Conclusion: </strong>The current study suggests that MDM2 immunohistochemical expression is a negative histoprognostic factor in GIST with a statistically significant correlation with metastasis.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"18 ","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2018-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-018-0069-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35802637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Comparison of a microsphere-based platform with a multiplex flow cytometric assay for determination of circulating cytokines in the mouse. 微球平台与多重流式细胞术测定小鼠循环细胞因子的比较。
Q2 Medicine Pub Date : 2018-01-06 eCollection Date: 2018-01-01 DOI: 10.1186/s12907-017-0068-6
Alain Stricker-Krongrad, Catherine Shoemake, Miao Zhong, Jason Liu, Guy Bouchard

Background: Measuring expression profiles of inflammatory biomarkers is important in monitoring the polarization of immune responses; therefore, results should be independent of quantitation methods if they are to be accepted as validated clinical pathology biomarkers. To evaluate effects of differing quantitation methods, the seven major circulating Th1/Th2/Th17 cytokines interleukin 2 (IL-2), interferon γ (IFN-γ), tumor necrosis factor α (TNF-α), IL-4, IL-6, IL-10 and IL-17A were quantified in plasma of lipopolysaccharide (LPS)-treated mice with two different multiplex platforms.

Methods: Female C57BL6 mice were treated orally with vehicle or dexamethasone, followed by LPS intravenously. Plasma samples were analyzed 0.5, 1, 2, 4, and 6 h post-LPS challenge with assays at Myriad-RBM and compared to assays performed on a BD Accuri C6 flow cytometer.

Results: IL-17A response to LPS was limited but sustained, and the response for the remaining cytokines were early and transient; dexamethasone reduced expression of all 7 cytokines. TNF-α and IL-6 levels were similar across both assays, and IL-4 levels were generally very low. Plasma levels of remaining cytokines were variably lower with BD assays than Myriad-RBM assays.

Conclusions: The present findings demonstrate that quantitation of circulating biomarkers of inflammation can be achieved using multiplexed flow cytometry, but careful consideration must be taken for assay validation when cross-referencing with another multiplexed assay.

背景:测量炎症生物标志物的表达谱对于监测免疫反应的极化是重要的;因此,如果结果要被接受为有效的临床病理生物标志物,那么结果应该独立于定量方法。为了评价不同定量方法的效果,我们采用两种不同的复合平台对脂多糖(LPS)处理小鼠血浆中7种主要的循环Th1/Th2/Th17细胞因子白介素2 (IL-2)、干扰素γ (IFN-γ)、肿瘤坏死因子α (TNF-α)、IL-4、IL-6、IL-10和IL-17A进行了定量。方法:雌性C57BL6小鼠口服给药或地塞米松,然后静脉注射LPS。血浆样品在lps刺激后0.5、1、2、4和6小时用Myriad-RBM进行分析,并与在BD Accuri C6流式细胞仪上进行的分析进行比较。结果:IL-17A对LPS的反应有限但持续,对其余细胞因子的反应早期且短暂;地塞米松降低了7种细胞因子的表达。两种检测中TNF-α和IL-6水平相似,IL-4水平普遍很低。与Myriad-RBM相比,BD检测的血浆剩余细胞因子水平有所降低。结论:目前的研究结果表明,使用多路流式细胞术可以实现炎症循环生物标志物的定量,但在与另一种多路流式细胞术交叉对照时,必须仔细考虑分析验证。
{"title":"Comparison of a microsphere-based platform with a multiplex flow cytometric assay for determination of circulating cytokines in the mouse.","authors":"Alain Stricker-Krongrad,&nbsp;Catherine Shoemake,&nbsp;Miao Zhong,&nbsp;Jason Liu,&nbsp;Guy Bouchard","doi":"10.1186/s12907-017-0068-6","DOIUrl":"https://doi.org/10.1186/s12907-017-0068-6","url":null,"abstract":"<p><strong>Background: </strong>Measuring expression profiles of inflammatory biomarkers is important in monitoring the polarization of immune responses; therefore, results should be independent of quantitation methods if they are to be accepted as validated clinical pathology biomarkers. To evaluate effects of differing quantitation methods, the seven major circulating Th1/Th2/Th17 cytokines interleukin 2 (IL-2), interferon γ (IFN-γ), tumor necrosis factor α (TNF-α), IL-4, IL-6, IL-10 and IL-17A were quantified in plasma of lipopolysaccharide (LPS)-treated mice with two different multiplex platforms.</p><p><strong>Methods: </strong>Female C57BL6 mice were treated orally with vehicle or dexamethasone, followed by LPS intravenously. Plasma samples were analyzed 0.5, 1, 2, 4, and 6 h post-LPS challenge with assays at Myriad-RBM and compared to assays performed on a BD Accuri C6 flow cytometer.</p><p><strong>Results: </strong>IL-17A response to LPS was limited but sustained, and the response for the remaining cytokines were early and transient; dexamethasone reduced expression of all 7 cytokines. TNF-α and IL-6 levels were similar across both assays, and IL-4 levels were generally very low. Plasma levels of remaining cytokines were variably lower with BD assays than Myriad-RBM assays.</p><p><strong>Conclusions: </strong>The present findings demonstrate that quantitation of circulating biomarkers of inflammation can be achieved using multiplexed flow cytometry, but careful consideration must be taken for assay validation when cross-referencing with another multiplexed assay.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"18 ","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2018-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-017-0068-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35717315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BMC Clinical Pathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1